MA48998A - Peptide d'activation du récepteur gip - Google Patents
Peptide d'activation du récepteur gipInfo
- Publication number
- MA48998A MA48998A MA048998A MA48998A MA48998A MA 48998 A MA48998 A MA 48998A MA 048998 A MA048998 A MA 048998A MA 48998 A MA48998 A MA 48998A MA 48998 A MA48998 A MA 48998A
- Authority
- MA
- Morocco
- Prior art keywords
- activation peptide
- receiver activation
- gip
- gip receiver
- peptide
- Prior art date
Links
- 101800001401 Activation peptide Proteins 0.000 title 1
- 102400000069 Activation peptide Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017072556 | 2017-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48998A true MA48998A (fr) | 2020-02-05 |
Family
ID=62089992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048998A MA48998A (fr) | 2017-03-31 | 2018-03-30 | Peptide d'activation du récepteur gip |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10435445B2 (fr) |
| EP (1) | EP3601329B1 (fr) |
| JP (2) | JP7175912B2 (fr) |
| KR (1) | KR102778100B1 (fr) |
| CN (1) | CN110709414B (fr) |
| AR (1) | AR111346A1 (fr) |
| AU (2) | AU2018246553B2 (fr) |
| BR (1) | BR112019020438A2 (fr) |
| CA (1) | CA3058361A1 (fr) |
| CL (1) | CL2019002790A1 (fr) |
| CO (1) | CO2019012271A2 (fr) |
| EA (1) | EA201992327A1 (fr) |
| EC (1) | ECSP19078239A (fr) |
| IL (1) | IL269581B2 (fr) |
| JO (2) | JOP20190211A1 (fr) |
| MA (1) | MA48998A (fr) |
| MY (1) | MY205279A (fr) |
| PE (1) | PE20200675A1 (fr) |
| PH (1) | PH12019502252A1 (fr) |
| SG (1) | SG11201908542QA (fr) |
| TW (1) | TWI801373B (fr) |
| WO (1) | WO2018181864A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3856339A1 (fr) * | 2018-09-24 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur gip et leurs utilisations |
| US12122815B2 (en) * | 2018-09-24 | 2024-10-22 | Takeda Pharmaceutical Company Limited | GIP receptor agonist peptide compounds and uses thereof |
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| EP4110800A1 (fr) * | 2020-03-06 | 2023-01-04 | Sanofi | Peptides servant d'agonistes sélectifs du récepteur gip |
| CN115916812A (zh) * | 2020-03-25 | 2023-04-04 | 武田药品工业株式会社 | Gip受体激动剂肽化合物及其用途 |
| CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
| WO2021198229A1 (fr) | 2020-03-31 | 2021-10-07 | Antaros Medical Ab | Agonistes sélectifs du récepteur de gip comprenant une fraction chélatante à des fins d'imagerie et de thérapie |
| EP4185607A1 (fr) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonistes au niveau des récepteurs de glp-1 et de gip appropriés pour une administration par voie orale |
| IL306122B2 (en) * | 2021-05-28 | 2026-01-01 | Guangdong Raynovent Biotech Co Ltd | Preparation and use of polypeptide |
| KR20240055069A (ko) | 2021-09-06 | 2024-04-26 | 사노피 | 효력있는 선택적 gip 수용체 작용제로서의 신규 펩티드 |
| EP4180060A1 (fr) | 2021-11-15 | 2023-05-17 | Adocia | Compositions solides comportant un peptide ou une protéine et un acide aminé acylé |
| EP4299057A1 (fr) | 2022-06-30 | 2024-01-03 | Adocia | Compositions solides comportant un peptide ou une protéine et un acide aminé acylé |
| WO2023084118A1 (fr) | 2021-11-15 | 2023-05-19 | Adocia | Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116891522B (zh) * | 2022-04-01 | 2024-05-14 | 南京知和医药科技有限公司 | 一种长效胰高血糖素样肽-1衍生物及其制备方法和用途 |
| US20260055142A1 (en) * | 2022-04-07 | 2026-02-26 | Guangdong Raynovent Biotech Co., Ltd. | Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof |
| EP4299052A1 (fr) | 2022-06-30 | 2024-01-03 | Adocia | Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation |
| EP4299071A1 (fr) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprenant un peptide ou une protéine et un acide aminé acylé |
| WO2024098718A1 (fr) * | 2022-11-07 | 2024-05-16 | 内蒙古博睿精创科技有限公司 | Nouveau composé polypeptidique à action prolongée, composition et utilisation associée |
| EP4687947A1 (fr) | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Modulateurs de l'activité du gip et intolérance orthostatique |
| TW202529796A (zh) * | 2023-11-22 | 2025-08-01 | 大陸商杭州中美華東製藥有限公司 | Glp-1r/gipr雙標靶激動劑在製備動物藥的用途 |
| WO2025154021A1 (fr) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur de gip améliorés et leurs utilisations |
| WO2025154020A1 (fr) * | 2024-01-19 | 2025-07-24 | Takeda Pharmaceutical Company Limited | Composés peptidiques agonistes du récepteur gip améliorés et leurs utilisations |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| BR0010750A (pt) | 1999-05-17 | 2002-02-26 | Conjuchem Inc | Peptìdeos insulinotrópicos de longa duração |
| CA2416384A1 (fr) | 2000-07-17 | 2003-01-16 | Takeda Chemical Industries, Ltd. | Derives de sulfonate, leur production et utilisation |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| AU2003278600A1 (en) | 2002-11-01 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
| CA2505322A1 (fr) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Agent de controle de la fonction recepteur |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| EP1630152A4 (fr) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | Compose cyclique condense |
| EP1669352A4 (fr) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | Derive thiazoline et utilisation |
| EP1695961A4 (fr) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | Derives d'uree, processus de production correspondant et utilisation |
| AU2004309271A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
| WO2005063725A1 (fr) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | Derives d'acide phenylpropanoique |
| JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| KR20070115947A (ko) | 2005-02-11 | 2007-12-06 | 아밀린 파마슈티칼스, 인크. | 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드 |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| WO2006121904A1 (fr) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Agonistes du recepteur du polypeptide insulinotropique gluco-dependant (gip) et procedes pharmacologiques d'utilisation associes |
| EP1916234B1 (fr) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Composé d'acide cyclopropanecarboxylique |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| TW200740435A (en) | 2005-08-10 | 2007-11-01 | Takeda Pharmaceuticals Co | Therapeutic agent for diabetes |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| CA2623412A1 (fr) | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement |
| CA2622069A1 (fr) | 2005-09-08 | 2007-03-15 | Uutech Limited | Traitement de l'obesite associee aux diabetes |
| WO2007109354A2 (fr) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci |
| RS53230B (sr) | 2006-06-27 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora |
| WO2008021560A2 (fr) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Analogue du gip et polypeptides hybrides possédant des propriétés sélectives |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
| RU2454415C9 (ru) | 2006-10-19 | 2013-02-27 | Такеда Фармасьютикал Компани Лимитед | Производное индола |
| EP2128138A1 (fr) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Composé de pyrazole |
| JP2010517935A (ja) | 2007-02-09 | 2010-05-27 | 武田薬品工業株式会社 | Ｐｐａｒ−ガンマのパーシャルアゴニストとしての縮合環化合物 |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| WO2008156757A1 (fr) | 2007-06-19 | 2008-12-24 | Takeda Pharmaceutical Company Limited | Composés d'indazole permettant d'activer la glucokinase |
| US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
| CN102105159B (zh) | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| KR20110043687A (ko) | 2008-08-07 | 2011-04-27 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체 |
| ES2574835T3 (es) | 2008-08-07 | 2016-06-22 | Ipsen Pharma S.A.S. | Análogos del polipéptido insulinotrópico dependiente de glucosa |
| WO2010016940A2 (fr) | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues de polypeptide insulinotrope glucose-dépendant |
| AU2009280021B2 (en) | 2008-08-07 | 2012-10-04 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal |
| PE20120332A1 (es) | 2008-12-19 | 2012-04-14 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida |
| EP2443146B1 (fr) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Composés de glucagon actifs sur le récepteur gip |
| WO2011014680A2 (fr) | 2009-07-31 | 2011-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Variantes du peptide inhibiteur gastrique et leurs utilisations |
| KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| US8507428B2 (en) | 2010-12-22 | 2013-08-13 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| WO2012088379A2 (fr) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Méthodes de traitement des affections métaboliques et de l'obésité faisant appel à des peptides associés au glucagon, actifs sur les récepteurs gip et glp-1 |
| US9453062B2 (en) | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| US20130090285A1 (en) | 2011-06-27 | 2013-04-11 | Phasebio Pharmaceuticals, Inc. | Methods of treatment with glp-1 receptor agonists |
| IN2014MN02304A (fr) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| CN104583232B (zh) | 2012-06-21 | 2018-04-13 | 印第安纳大学研究及科技有限公司 | 展现gip受体活性的胰高血糖素类似物 |
| PE20150863A1 (es) | 2012-06-21 | 2015-06-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad de receptor de gip |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| SI3004155T1 (sl) * | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| US20160185837A1 (en) | 2013-08-16 | 2016-06-30 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015067715A2 (fr) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Composés agonistes doubles de gip et glp-1 et procédés associés |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015086728A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Analogues peptidiques de l'exendine 4 en tant qu'agonistes mixtes des récepteurs glp-1/gip |
| EP3080154B1 (fr) | 2013-12-13 | 2018-02-07 | Sanofi | Agonistes doubles du récepteur glp-1/gip |
| EP3080152A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Analogues peptidiques de l'exendine 4 non acylés |
| GB2528436A (en) | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| ES2685987T3 (es) | 2014-09-05 | 2018-10-15 | University Of Copenhagen | Análogos de péptidos gip |
| KR102620911B1 (ko) | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| WO2016077220A1 (fr) | 2014-11-10 | 2016-05-19 | Mb2 Llc | Co-agonistes peptidiques du gip/glp-1 destinés à être administrés à des humains |
| JP2018012644A (ja) | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| TWI582109B (zh) | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| JP6326394B2 (ja) | 2015-10-09 | 2018-05-16 | Ｋｙｂ株式会社 | ミキサ車の積載量計量装置 |
| EP3368556B1 (fr) | 2015-10-28 | 2024-04-10 | Tufts University | Nouveaux polypeptides présentant une meilleure stabilité et procédés de préparation et d'utilisation associés |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| JP6995042B2 (ja) | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
-
2017
- 2017-06-16 JO JOP/2019/0211A patent/JOP20190211A1/ar unknown
-
2018
- 2018-03-28 AR ARP180100762A patent/AR111346A1/es unknown
- 2018-03-29 JO JOP/2018/0028A patent/JOP20180028A1/ar unknown
- 2018-03-30 EA EA201992327A patent/EA201992327A1/ru unknown
- 2018-03-30 EP EP18721166.9A patent/EP3601329B1/fr active Active
- 2018-03-30 MA MA048998A patent/MA48998A/fr unknown
- 2018-03-30 PE PE2019001962A patent/PE20200675A1/es unknown
- 2018-03-30 AU AU2018246553A patent/AU2018246553B2/en active Active
- 2018-03-30 KR KR1020197028353A patent/KR102778100B1/ko active Active
- 2018-03-30 BR BR112019020438A patent/BR112019020438A2/pt unknown
- 2018-03-30 IL IL269581A patent/IL269581B2/en unknown
- 2018-03-30 JP JP2019553587A patent/JP7175912B2/ja active Active
- 2018-03-30 US US15/941,030 patent/US10435445B2/en active Active
- 2018-03-30 CN CN201880035168.2A patent/CN110709414B/zh active Active
- 2018-03-30 MY MYPI2019005632A patent/MY205279A/en unknown
- 2018-03-30 WO PCT/JP2018/013540 patent/WO2018181864A1/fr not_active Ceased
- 2018-03-30 CA CA3058361A patent/CA3058361A1/fr active Pending
- 2018-03-30 TW TW107111293A patent/TWI801373B/zh active
- 2018-03-30 SG SG11201908542Q patent/SG11201908542QA/en unknown
-
2019
- 2019-08-29 US US16/555,085 patent/US11174301B2/en active Active
- 2019-09-30 PH PH12019502252A patent/PH12019502252A1/en unknown
- 2019-09-30 CL CL2019002790A patent/CL2019002790A1/es unknown
- 2019-10-30 EC ECSENADI201978239A patent/ECSP19078239A/es unknown
- 2019-10-31 CO CONC2019/0012271A patent/CO2019012271A2/es unknown
-
2022
- 2022-02-09 AU AU2022200837A patent/AU2022200837A1/en not_active Abandoned
- 2022-11-09 JP JP2022179703A patent/JP2023012547A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA48998A (fr) | Peptide d'activation du récepteur gip | |
| PL3727460T3 (pl) | Bicykliczne ligandy peptydowe swoiste wobec epha2 | |
| IL268920A (en) | Peptide vaccines | |
| DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| CL2018000692S1 (es) | Manguera flexible | |
| EP3456017A4 (fr) | Hypothèses de colocalisation d'antennes et de récepteurs | |
| EP3897128A4 (fr) | Peptides antimicrobiens | |
| EP3589873A4 (fr) | Ensemble de montage de tuyau souple | |
| SG11202005653RA (en) | Novel peptide | |
| EP3480212C0 (fr) | Peptide il13ralpha2 et ses utilisations | |
| EP3418079A4 (fr) | Récepteur | |
| IT201700080068A1 (it) | Peptidi antimicrobici | |
| EP3794014A4 (fr) | Agent d'activation de peptide | |
| EP3792349A4 (fr) | Macrocyclase peptidique | |
| EP3893519A4 (fr) | Récepteur | |
| EP3697808C0 (fr) | Peptide neuroprotecteur | |
| FI11968U1 (fi) | Kellokauluri | |
| EP3502026C0 (fr) | Structure d'enroulement de tuyau | |
| EP3595896C0 (fr) | Tuyau flexible | |
| EP3730143A4 (fr) | Association de l'omidénépag | |
| UA38662S (uk) | Емблема | |
| UA38760S (uk) | Емблема | |
| UA40329S (uk) | Каністра | |
| UA40451S (uk) | Каністра |